Albumin-Coated Mesoporous Polydopamine Nanoparticles for Renal Delivery of Epigallocatechin Gallate against Cisplatin-Induced Acute Kidney Injury
- 31 August 2026
- journal article
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 18 (35) , 47461-47480
Abstract
Cisplatin-induced acute kidney injury (AKI) remains a serious clinical complication, with excessive reactive oxygen species (ROS) recognized as key contributors. The natural antioxidant epigallocatechin-3-gallate (EGCG) shows promise in mitigating oxidative stress–related damage. However, its clinical application is limited by poor stability and low renal bioavailability. To address this, we developed a biocompatible nanoplatform by encapsulating EGCG within mesoporous polydopamine nanoparticles (EGCG-MPDA). Ultrasmall nanoparticles (<10 nm or <20 kDa) undergo rapid glomerular filtration and renal clearance, limiting therapeutic retention. While uncoated MPDA nanoparticles (∼200 nm) are large enough to avoid renal filtration, their size renders them highly susceptible to opsonization and MPS sequestration. To address this MPS-mediated clearance, we coated MPDA with a preclinically used BSA shell to create EGCG-MPDA@BSA. The biocompatible BSA corona acts as a “stealth” layer to attenuate opsonization, reduce early hepatic sequestration, and enhance interactions with peritubular endothelial cells, promoting nanoparticle passage into injured tubular epithelial cells. In a murine cisplatin-induced AKI model, EGCG-MPDA@BSA exhibited significantly enhanced therapeutic efficacy compared to uncoated nanoparticles and free EGCG. Transcriptomic and biochemical analyses revealed that its superior therapeutic efficacy arises from the activation of the Nrf2/HO-1/GPX4 antioxidant pathway, thereby alleviating oxidative stress, inflammation, and tubular damage. Collectively, this work presents an albumin corona strategy that enables effective renal retention of large nanoparticles, offering a safe, translatable approach for localized AKI therapy.Keywords
Funding Information
- Beijing Natural Science Foundation (Grant No. L232016)
This publication has 49 references indexed in Scilit:
- Albumin-based nanocarriers: Singularities, synthesis methods, clinical relevance and targeting strategies in cancerActa Pharmaceutica Sinica B, 2025
- Polydopamine Nanodots Ameliorate Inflammatory Bowel Disease by Restoring Redox Homeostasis and Intestinal MicroenvironmentAdvanced Science, 2025
- Creating Single Atomic Coordination for Hypoxia‐Resistant Pyroptosis Nano‐Inducer to Boost Anti‐Tumor ImmunotherapyAdvanced Materials, 2025
- Evaluation of Reactive Oxygen Species Scavenging of Polydopamine with Different NanostructuresAdvanced Healthcare Materials, 2023
- Manipulating the antioxidative capacity of melanin-like nanoparticles by involving condensation polymerizationScience China Chemistry, 2023
- Cisplatin in cancer treatmentBiochemical Pharmacology, 2022
- Bovine Serum Albumin-Conjugated Ferrimagnetic Iron Oxide Nanoparticles to Enhance the Biocompatibility and Magnetic Hyperthermia PerformanceNano-Micro Letters, 2015
- Kidney–targeted drug delivery systemsActa Pharmaceutica Sinica B, 2014
- Preformed albumin corona, a protective coating for nanoparticles based drug delivery systemBiomaterials, 2013
- Drug targeting to the kidney: Advances in the active targeting of therapeutics to proximal tubular cells☆Advanced Drug Delivery Reviews, 2010